Business Context and Reporting Period
This Form 8-K Current Report was filed by Actinium Pharmaceuticals, Inc. on April 27, 2018. The filing discloses the appointment of a new independent director and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on corporate governance and executive compensation.
Material Changes
The primary material change reported is the appointment of Jeffrey W. Chell, M.D., as a Class II independent director on April 27, 2018. Dr. Chell was also appointed to the Audit Committee and Compensation Committee.
Compensation and Agreements
- Cash Compensation: Dr. Chell is entitled to $40,000 per year, payable in quarterly installments.
- Equity Grant: Dr. Chell was granted 75,000 stock options with a 10-year term. The exercise price equals the share price on April 27, 2018.
- Vesting Schedule: 28% of the options vest on the 12-month anniversary of the commencement date, with the remaining balance vesting at 2% per month thereafter.
- Additional Agreements: Dr. Chell entered into an Indemnity Agreement and a Confidential Information and Invention Assignment Agreement.
Investor Verification Points
- Verify the exact exercise price of the 75,000 options granted to Dr. Chell based on the stock price on April 27, 2018.
- Confirm Dr. Chell's independence status and any potential conflicts of interest given his background with the National Marrow Donor Program and CLR Insurance.
- Review the full text of the Director Agreement (Exhibit 10.1) for any additional terms not summarized in the filing.
- Monitor the upcoming 2018 annual shareholders meeting where Dr. Chell will be up for election for a three-year term.